ArticleThe Lancet. Infectious diseases2020

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.

Pedro M Folegatti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.